Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients | Zendy

Lars Melholt Rasmussen | Zendy; Lise Tarnow | Zendy; Troels Krarup Hansen | Zendy; HansHenrik Parving | Zendy; Allan Flyvbjerg | Zendy

Open Access

Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients

Author(s) -

Lars Melholt Rasmussen,

Lise Tarnow,

Troels Krarup Hansen,

HansHenrik Parving,

Allan Flyvbjerg

Publication year - 2005

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje.1.02049

Subject(s) - medicine , osteoprotegerin , endocrinology , blood pressure , diabetes mellitus , renal function , diabetic nephropathy , type 2 diabetes , nephropathy , creatinine , kidney disease , receptor , activator (genetics)

The bone-related peptide osteoprotegerin (OPG) has recently been found in increased amounts in the vasculature in diabetes. It is produced by vascular smooth muscle and endothelial cells, and may be implicated in the development of vascular calcifications. OPG is present in the circulation, where increased amounts have been observed in patients with diabetes. In this study, we examined whether plasma OPG is associated with the glycaemic and vascular status of patients with type 1 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research